The Will to Live; Unhealthy Gut Bacteria; Promise of Genomic Testing Evolves

An oncologist wonders whether the will to live or deciding to let go has more to do with survival than all that modern treatment has to offer. (JCO Art of Oncology)

An unhealthy mix of gut microbiota may play a role in breast cancer metastasis. (UVA Health)

Exercise-induced increases in HDL cholesterol helped reduce frailty — a marker for worse outcome — in patients with chronic lymphocytic leukemia. (University of Surrey, Duke University Medical Center)

Black women and white women may respond differently to endocrine therapy for breast cancer. (American Association for Cancer Research)

One of the most comprehensive investigations to date provided new insight into associations between social determinants of health and inequities in cancer care. (American Cancer Society, Journal of the National Cancer Institute)

The risk of liver cancer among Hispanic/Latino individuals living in North America may increase with each successive generation. (American Association for Cancer Research)

More evidence in support of universal germline genetic testing to inform treatment decisions for newly diagnosed breast cancer. (JAMA Network Open)

A genomic test panel showed promise for identifying African American men at high risk for prostate cancer. (Moffit Cancer Center)

Identifying “critical genomic changes” in prostate cancer may lead to new strategies to overcome resistance to commonly used hormonal therapies. (Mayo Clinic, Molecular Cancer Research)

Updated guidance for COVID-19 vaccination among patients with cancer. (National Comprehensive Cancer Network)

Studies involving clinical models suggest that loading cancer drugs into tiny lipid particles (nanoliposomes) may improve delivery of the drugs to tumors. (FASEB Journal)

An investigational combination of trifluridine/tipiracil (Lonsurf) plus bevacizumab (Avastin) significantly improved overall survival in refractory metastatic colorectal cancer, Servier and Taiho announced.

QT Imaging announced FDA clearance of a technique to calculate fibroglandular volume in the breast as a means of assessing breast cancer risk and response to breast cancer treatment.

Noted urologic oncologist Nicholas Vogelzang, MD, of Comprehensive Cancer Centers of Nevada, died Tuesday at the age of 72. (Las Vegas Review-Journal)